[FG] Hess Viviane

Panje C et al. (2022) ‘Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial’, European Journal of Cancer, 177, pp. 186–193. Available at: https://doi.org/10.1016/j.ejca.2022.09.035.

Kelly RJ et al. (2021) ‘Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer’, New England Journal of Medicine, 384(13), pp. 1191–1203. Available at: https://doi.org/10.1056/nejmoa2032125.

Fehr M et al. (2020) ‘High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08’, BMC Cancer, 20(1), p. 166. Available at: https://doi.org/10.1186/s12885-020-6623-z.

Grossert, Astrid et al. (2019) ‘A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): Study protocol’, BMC Psychology, 7(1). Available at: https://doi.org/10.1186/s40359-019-0357-1.

Streckmann F et al. (2019) ‘Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: Study protocol of a randomised controlled trial-VANISH’, BMJ Open, 9(4), p. e024467. Available at: https://doi.org/10.1136/bmjopen-2018-024467.

Grossert, Astrid et al. (2019) ‘A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): study protocol’, BMC psychology, 7(1), p. 90. Available at: https://doi.org/10.1186/s40359-019-0357-1.

Ruhstaller T et al. (2018) ‘Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: A randomized, open-label, phase III trial (SAKK 75/08)’, Annals of Oncology, 29(6), pp. 1386–1393. Available at: https://doi.org/10.1093/annonc/mdy105.

Wicki A et al. (2018) ‘First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)’, European Journal of Cancer, 96, pp. 6–16. Available at: https://doi.org/10.1016/j.ejca.2018.03.012.

Tondorf, T. et al. (2018) ‘Focusing on cancer patients” intentions to use psychooncological support: A longitudinal, mixed-methods study’, Psycho-Oncology, 27(6), pp. 1656–1663. Available at: https://doi.org/10.1002/pon.4735.

Urech, Corinne et al. (2018) ‘Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study’, Journal of clinical oncology, 36(8), pp. 780–788. Available at: https://doi.org/10.1200/jco.2017.74.8491.

Hess V et al. (2017) ‘Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome’, Clinical Colorectal Cancer, 16(3), pp. 240–245. Available at: https://doi.org/10.1016/j.clcc.2016.07.008.

Grossert A, Meinlschmidt G and Schaefert R (2017) ‘A case series report of cancer patients undergoing group body psychotherapy’, F1000Research. 05.09.2017, 6, p. 1646. Available at: https://doi.org/10.12688/f1000research.12262.1.

Grossert, Astrid et al. (2016) ‘Web-based stress management for newly diagnosed cancer patients (STREAM-1): A randomized, wait-list controlled intervention study’, BMC Cancer, 16(1). Available at: https://doi.org/10.1186/s12885-016-2866-0.

Conen, Katrin et al. (2016) ‘Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort’, Journal of Cancer, 7(14), pp. 2110–2116. Available at: https://doi.org/10.7150/jca.16211.

Grossert, A. et al. (2016) ‘Web-based stress management for newly diagnosed cancer patients (STREAM-1): A randomized, wait-list controlled intervention study’, BMC Cancer, 16(1), p. 838. Available at: https://doi.org/10.1186/s12885-016-2866-0.

Hagmann R et al. (2015) ‘Second-line therapy of small-cell lung cancer: Topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO) - A single center experience’, Journal of Cancer, 6(11), pp. 1148–1154. Available at: https://doi.org/10.7150/jca.13080.

Köberle, D. et al. (2015) ‘Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)’, Annals of Oncology, 26(4), pp. 14–709. Available at: https://doi.org/10.1093/annonc/mdv011.

Kasenda, Benjamin et al. (2014) ‘Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study’, BMC Cancer, 14, p. 728. Available at: https://doi.org/10.1186/1471-2407-14-728.

Schmidt N et al. (2013) ‘Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies’, European Radiology, 23(3), pp. 632–639. Available at: https://doi.org/10.1007/s00330-012-2640-x.

Hess, Viviane and Hess, Viviane (2011) ‘Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma : a Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)’, Journal of clinical oncology, 29(6), pp. 31–626. Available at: https://doi.org/10.1200/jco.2010.31.9715.

Bernhard, J et al. (2010) ‘Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy’, British journal of cancer, 103(9), pp. 24–1318. Available at: https://doi.org/10.1038/sj.bjc.6605929.

Herrmann, R. and Herrmann, R. (2010) ‘Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC) : a phase I/II trial’, Annals of oncology, 21(12), pp. 5–2390. Available at: https://doi.org/10.1093/annonc/mdq242.

Hess, Vivianne (2010) ‘Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma : a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)’, The oncologist, 15(3), pp. 92–285. Available at: https://doi.org/10.1634/theoncologist.2009-0316.

Popescu, R. (2009) ‘Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)’, Annals of oncology : official journal of the European Society for Medical Oncology, 20(9), pp. 8–1522. Available at: https://doi.org/10.1093/annonc/mdp045.

Ribi, Karin et al. (2009) ‘Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?’, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 17(8), pp. 16–1109. Available at: https://doi.org/10.1007/s00520-008-0570-6.

Hess V et al. (2008) ‘Interleukin-2-based biochemotherapy for patients with stage IV melanoma: Long-term survivors outside a clinical trial setting’, Oncology, 73(1-2), pp. 33–40. Available at: https://doi.org/10.1159/000120029.

Borner, M et al. (2008) ‘Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer : a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK’, Annals of oncology, 19(7), pp. 92–1288. Available at: https://doi.org/10.1093/annonc/mdn058.

Hess, Viviane (2008) ‘[Surveillance after primary resection of esophageal, gastric, pancreatic, hepatobiliary cancer and gastrointestinal stroma tumor (GIST)]’, Therapeutische Umschau, 65(6), pp. 51–347. Available at: https://doi.org/10.1024/0040-5930.65.6.347.

Hess, Viviane (2008) ‘[Adjuvant!Online--an Internet-based decision tool for adjuvant chemotherapy in early breast cancer]’, Therapeutische Umschau, 65(4), pp. 5–201. Available at: https://doi.org/10.1024/0040-5930.65.4.201.

Hess, Viviane et al. (2008) ‘CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial’, The Lancet oncology, 9(2), pp. 8–132. Available at: https://doi.org/10.1016/s1470-2045(08)70001-9.

Koeberle, D et al. (2008) ‘Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer’, British journal of cancer, 98(7), pp. 9–1204. Available at: https://doi.org/10.1038/sj.bjc.6604297.

Gick U et al. (2007) ‘Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: A phase II report of the SAKK’, Oncology. 05.03.2007, 71(1-2), pp. 54–60. Available at: https://doi.org/10.1159/000100449.

Ruhstaller,T and Hess,V (2006) ‘Das Oesophaguskarzinom’, Onkologie, 3(5), pp. 2–6.

Hess V et al. (2004) ‘Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment’, Journal of Clinical Oncology, 22(6), pp. 1040–1044. Available at: https://doi.org/10.1200/jco.2004.08.078.

Regamey N et al. (2004) ‘Infection with human herpesvirus 8 and transplant-associated gammopathy’, Transplantation, 77(10), pp. 1551–1554. Available at: https://doi.org/10.1097/01.tp.0000129065.31427.96.

Hess V et al. (2003) ‘Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma’, Annals of Oncology, 14(4), pp. 638–642. Available at: https://doi.org/10.1093/annonc/mdg176.

Hess V et al. (2003) ‘Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial’, Journal of Clinical Oncology, 21(1), pp. 66–68. Available at: https://doi.org/10.1200/jco.2003.04.029.